WO2018062733A1 - Composition comprenant un extrait de thé vert pour améliorer la régulation du glucose sanguin, préparée à l'aide d'eau de mer de lave dessalée - Google Patents

Composition comprenant un extrait de thé vert pour améliorer la régulation du glucose sanguin, préparée à l'aide d'eau de mer de lave dessalée Download PDF

Info

Publication number
WO2018062733A1
WO2018062733A1 PCT/KR2017/010124 KR2017010124W WO2018062733A1 WO 2018062733 A1 WO2018062733 A1 WO 2018062733A1 KR 2017010124 W KR2017010124 W KR 2017010124W WO 2018062733 A1 WO2018062733 A1 WO 2018062733A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
green tea
lava seawater
tea extract
improving
Prior art date
Application number
PCT/KR2017/010124
Other languages
English (en)
Korean (ko)
Inventor
김수경
정진오
김아영
정현우
김완기
김정기
Original Assignee
주식회사 아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 아모레퍼시픽 filed Critical 주식회사 아모레퍼시픽
Publication of WO2018062733A1 publication Critical patent/WO2018062733A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/332—Promoters of weight control and weight loss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Definitions

  • the present invention relates to a composition for improving blood sugar control comprising a green tea extract prepared using desalted lava seawater, and more particularly, comprising a green tea extract prepared using desalted Jeju lava seawater as an extractant as an active ingredient. It relates to a composition for improving blood sugar control.
  • Metabolic syndrome refers to a combination of diseases such as impaired glucose tolerance, hypertension, hyperlipidemia, obesity, and cardiovascular atherosclerosis due to chronic metabolic disorders that last for more than six months or one year. According to various epidemiologic data to date, about 25% of the population of developed and developing countries have metabolic syndrome, and the prevalence rate in Korea continues to increase. Metabolic syndrome is clinically closely related to two major diseases. One is various cardiovascular diseases caused by atherosclerosis, and metabolic syndrome increases the risk of coronary artery disease, cerebrovascular and peripheral vascular disease by 2-3 times. It is known to let. In addition, metabolic syndrome is a prognostic disease of type 2 diabetes, and as metabolic syndrome develops and leads to diabetes, the risk of associated cardiovascular disease is also amplified.
  • Metabolic syndrome has four clinical symptoms.
  • obesity causes more weight than the standard and the ratio of waist circumference to hip circumference increases.
  • insulin resistance due to insulin resistance, diabetes is not only defective in insulin itself, but also due to obesity or lack of exercise, insulin receptors are reduced and insulin secretion does not work.
  • the concentration of cholesterol and triglycerides in the blood increases, defects in lipid metabolism occur, and the concentration of lipids in the blood increases, resulting in cardiovascular diseases of hyperlipidemia and cardiovascular atherosclerosis.
  • the last symptom is high blood pressure. Metabolic processes, such as the removal of lipids in blood vessels, cause defects in lipid accumulation and thereby increase blood pressure.
  • Metabolic syndrome a chronic disease, is a disease that usually results from lifestyle, and it is known that it can be treated to some extent by changing this habit. In the gown, treatment through dietary habits is suggested as the most effective method.
  • Atherosclerotic disease in particular, is a major disease that increases mortality and morbidity among modern people. Atherosclerosis is a symptom due to the precipitation of lipids and calcium in the artery linings associated with inflammation. These symptoms include the accumulation of endothelial cells, lipids, and mononuclear cells that affect the vortices of blood such as hypercholesterolemia, hypertension, obesity, and diabetes. Will be affected.
  • Fat cells are one of the major cells for glucose metabolism and play a very important role in blood sugar control.
  • Glucose transport is carried out by glucose transporters (GLUTs), and in order to increase glucose transport, the expression of glucose transporters and the positional shift of the receptors to the cell membrane must be increased. Metastasis of the receptor to the cell membrane is known to be involved in signaling by insulin.
  • 'Insulin' is a hormone that regulates the blood sugar, and when the concentration of glucose in the blood increases the insulin secretion in the pancreas increases glucose into the cells, thereby maintaining a constant concentration of glucose in the blood at all times.
  • the body's insulin sensitivity (effect) and insulin secretion are balanced so that blood sugar is always regulated within the normal range.
  • blood sugar cannot be used to increase the concentration of insulin in the blood.
  • the body's susceptibility to insulin is reduced, increasing insulin resistance.
  • the insulin resistance leads to a weak state of promoting the absorption of sugar, which is the main action of insulin in skeletal muscle, fat cells, and liver. Due to such insulin resistance, even if the amount of insulin in the body is about the same, the blood glucose lowering action is weakened, and accordingly, more insulin is required to maintain blood sugar normal.
  • hyperinsulinemia the phenomenon in which a large amount of insulin is secreted into the body to supplement insulin resistance.
  • excessive secretion of insulin increases appetite, promotes fat synthesis, and inhibits lipolysis, thereby inducing obesity. That is, the problem of insulin resistance is reported to be closely related to metabolic syndrome such as diabetes, hypertension, obesity.
  • 'Diabetes' refers to a disorder in which the balance between insulin sensitivity and insulin secretion in the body is broken, that is, insulin deficiency or insulin sensitivity is lowered and glucose is released into the urine because blood sugar is not controlled due to inability to use sugar in the blood. .
  • Diabetes is largely divided into type 1 diabetes and type 2 diabetes.
  • Type 1 diabetes mellitus 'insulin dependent diabetes mellitus'
  • Type 2 diabetes refers to a condition in which blood sugar levels are higher than normal and occurs when the balance of insulin secretion and the secretion of insulin from the pancreas is broken in peripheral tissues such as muscle, fat and liver. do. Most diabetics have insulin resistance and hyperinsulinemia before progressing to type 2 diabetes.
  • type 2 diabetes lowers the action of insulin, which lowers the initial blood sugar level, resulting in insulin resistance that does not effectively absorb sugar and utilize it as energy in peripheral tissues, resulting in increased insulin secretion to lower high blood sugar. Hyperinsulinemia is seen. Failure to overcome this will eventually lead to type 2 diabetes. In Korea, the number of patients with type 2 diabetes has increased in recent decades.
  • the prescription of insulin, insulin secretagogue or hypoglycemic agent is mainly used to treat diabetes and diabetic complications.
  • this treatment is limited in that it is not a fundamental disease treatment.
  • a method of improving insulin resistance or increasing insulin sensitivity has recently been proposed for the treatment of metabolic syndrome-related diseases including diabetes and diabetic complications or metabolic syndrome itself. That is, attempts have been made to treat diabetes and diabetic complications by returning blood glucose and triglyceride levels to normal to eliminate the need for external insulin or to reduce the concentration of insulin.
  • pancreatic beta cell insulin secretion Two characteristics of type 2 diabetes are insulin resistance and pancreatic beta cell insulin secretion. In addition to certain genetic factors, acquired factors, such as obesity or frequent exposure to hyperglycemia, facilitate and intensify the development of diabetes. Frequent hyperglycemic exposure thus increases insulin resistance and causes beta cell dysfunction and death due to overload of pancreatic beta cells that secrete insulin. This is called glucose toxicity (Borona, 2008). As a type of early-onset type 2 diabetes, mutations in the glucokinase gene are characterized by inhibiting hepatic glucose uptake, resulting in postprandial hyperglycemia (Jiang et al., 2008), leading to glucose toxicity.
  • Amylase inhibitors or glucosidase inhibitors are commercially available to reduce hyperglycemia after eating, but they can cause side effects in the gastrointestinal tract, such as loss of appetite and indigestion, by preventing mutations to monosaccharides. .
  • Green tea is a perennial evergreen plant belonging to the tea tree family, and has been drinking since the Three Kingdoms period, and recently, its value has been recognized as the functionalities of the green tea ingredients are gradually revealed.
  • Green tea contains a large amount of useful ingredients such as polyphenols, caffeine, amino acids, and vitamin C. It has been found to be excellent for hangover and nicotine detoxification, fatigue recovery, cardiac action, and skin care. Antioxidant action, anti-cholesterol action, hypoglycemic action, anti-tumor action, platelet aggregation inhibitory effect on polyphenols have been proved, and its functionality has attracted much attention.
  • the leaves of the tea plant contain up to 36% polyphenols on a dry weight basis, but their composition varies depending on climate, season, variety and growth conditions.
  • Green tea catechins are a major group of green tea polyphenols.
  • Tea quality is greatly influenced by the harvesting season, maturity, varieties and the surrounding environment such as soil, weather, fertilization, and the tea's chemistry changes according to the external conditions.
  • the taste of green tea is a combination of astringent, bitter, umami and subtle sweetness.
  • the bitterness and bitterness are due to catechin and caffeine, the umami is mainly due to amino acids, and free catechin is known to give sweetness to the aftertaste.
  • Catechin the main physiologically active substance of green tea, is a polyphenol containing about 100 mg in a cup of green tea, mainly epigallocatechin gallate (hereinafter referred to as "EGCG”) and epicatechin gallate (epicatechin gallate).
  • EGCG epigallocatechin gallate
  • GC epicatechin gallate
  • EC epigallocatechin
  • ECC epigallocatechin
  • catechins are food materials having various bioregulatory functions such as anti-caries, antibacterial, antioxidant, deodorant action, blood glucose level and blood cholesterol elevation suppression, anti-tumor, and lipid peroxide production inhibitory action.
  • these catechins are known to have three to four times the antioxidant effect of vitamin C and vitamin E.
  • catechins are water-soluble, but tea leaves also contain fat-soluble components such as vitamin E and ⁇ -carotene. These components are used to remove free radicals and active oxygen-derived products that adversely affect immune response or cancer in vivo. It is known to be involved, and at the same time, it can be expected that synergistic effects can be expected when ingested with catechins, which simultaneously act as antioxidants.
  • GC gallate catechin
  • Magma Seawater is a water that has been aged for a long time after seawater has been naturally filtered through basalt and sanisil layers. It is a seawater that exists in freshwater groundwater and saltwater, that is, in a saltwater mixing zone. Jeju Special Self-Governing Republic is distributed from Jocheon-eup to Namwon-eup and Seongsan-eup.
  • lava seawater contains not only essential minerals such as sodium, magnesium, calcium and potassium, but also general useful minerals (iron, manganese, zinc, molybdenum, etc.) than deep seawater and deep water than general seawater and deep water. . Characteristically, lava seawater contains a large amount of useful components, so the industrial utilization value is very high.
  • Lava seawater is a clean groundwater resource with no detectable coliforms, nitrates, phosphates, or phenols, and lava saltwater obtained from this lava seawater because no harmful components such as arsenic, mercury, cadmium, or lead are detected. We believe that there are no obstacles to industrialization.
  • Patent Document 1 discloses a method for producing green tea leaves that increase the content of catechins, polyphenols, flavonoids and the like of green tea leaves using deep sea water as a method of producing high-functional green tea leaves
  • Patent Document 2 discloses a green tea extract composition having a high content of minerals and minerals such as catechins and polyphenols using deep sea water, and antioxidant, whitening, anti-wrinkle of green tea extract composition prepared using deep sea water as an extraction solvent, Although it discloses an anti-inflammatory effect, it is prepared using Jeju desalted lava seawater, and containing the green tea extract as an active ingredient, there is no disclosure about the composition for improving blood sugar control.
  • composition for improving blood sugar control including green tea extract prepared using desalted Jeju lava seawater as an extractant.
  • Patent Document 1 Korean Registered Patent No. 10-1002589 (2010.12.14)
  • Patent Document 2 Korean Patent Registration No. 10-0959520 (2010.05.17)
  • the present invention provides a composition for improving blood sugar control comprising a green tea extract prepared by using desalted lava seawater desalted lava seawater as an active ingredient.
  • the present invention also provides a pharmaceutical composition for improving blood sugar metabolism or improving obesity, containing the composition as an active ingredient.
  • the present invention also provides a health functional food composition for improving blood sugar metabolism or improving obesity containing the composition as an active ingredient.
  • the present invention also provides a cosmetic composition for improving blood sugar metabolism or improving obesity containing the composition as an active ingredient.
  • the present invention also provides a method for improving blood glucose metabolism or improving obesity, wherein the green tea extract prepared using desalted lava seawater desalted from lava seawater is used as a blood glucose metabolism improving agent or an obesity improving agent. to provide.
  • the present invention also provides the use of green tea extract prepared using desalted lava seawater desalted lava seawater as a blood sugar metabolism improving agent or obesity improving agent in the manufacture of a dietary supplement composition for improving blood glucose metabolism or improving obesity. do.
  • the present invention also provides the use of green tea extract prepared using desalted lava seawater desalted lava seawater as a blood sugar metabolism improving agent or obesity improving agent in the manufacture of cosmetic compositions or cosmetics for improving blood sugar metabolism or improving obesity. do.
  • Green tea extract prepared by using the desalted lava seawater according to the present invention can be used in the manufacture of medicines, functional foods and cosmetics that can improve the blood sugar level and reduce the risk of cardiovascular disease through the activation of biological functions.
  • 1 shows a method for producing desalted lava seawater.
  • 2 is a graph showing the composition of the green tea extract prepared using desalted lava seawater.
  • Figure 3 shows the change in glucose transport capacity of adipocytes after the green tea extract prepared using desalted lava seawater to the adipocytes.
  • the present invention relates to a composition for improving blood sugar control, comprising a green tea extract prepared by using demineralized lava seawater prepared by mixing mineral water with demineralized water desalted from Jeju lava seawater.
  • 'demineralized lava seawater' is obtained by mixing demineralized water obtained by reverse osmosis filtration (RO) of the collected Jeju lava seawater with mineral water obtained by electrodialysis (ED) of the collected Jeju lava seawater. Prepared (see FIG. 1).
  • RO reverse osmosis filtration
  • ED electrodialysis
  • the composition of the green tea extract was analyzed the composition of the green tea extract.
  • glucose transport ability was measured.
  • the adipocytes treated only with distilled water or demineralized lava seawater did not have a statistically significant change in glucose transport ability, whereas the green tea extract extracted with demineralized lava seawater was compared with the green tea extract extracted with distilled water. Glucose traffic increased significantly.
  • the present invention relates to a composition for improving blood sugar control, comprising, as an active ingredient, green tea extract prepared by using desalted lava seawater desalted lava seawater.
  • the lava sea water defined in the present invention is excavated from 100 to 200m underground, preferably 150m underground in the basement of Handong-ri, Gujwa-eup, Bukjeju-gun, Eastern Jeju, 30-150m underground, preferably 44.35m, 86.35m or 126.35m underground.
  • Intake of lava saltwater The lava seawater is sterilized using a sterile filter, and then obtained in a dried form (for example, lava saltwater) using a method such as heating evaporation, vacuum evaporation, sun drying or ventilation drying, and then distilled water. It may be dissolved in an aqueous solution to prepare a composition for use in preparing various formulations.
  • the lava seawater may be used as drinking water when only the desalting step is adopted, and when the dehydration step is adopted, the lava seawater may be used as a mineral composition powder mixed with salts. When the dehydration step is complete, it can be used as a pure (salt-free) mineral composition powder.
  • the desalted lava water of the present invention specifically comprises V, Se, Ge, Fe, Zn, Mn, Sr, B, Mo, Na, Mg, K, Ca and Si. All of these minerals are minerals that have been found to be useful to the human body.
  • Green tea extract prepared using desalted lava seawater desalted from lava seawater according to the present invention is 0.01 to 50% by weight, preferably 0.1 to 50% by weight, and more preferably 0.1 to 10% by weight, based on the total weight of the composition. It may be contained. If it is less than 0.01% by weight, the effect of improving blood sugar control is insignificant, and if it exceeds 50% by weight, the formulation stability becomes worse, which is not preferable.
  • the green tea extract is added to 70 ⁇ 100 °C desalted lava seawater to the green tea for 1 to 24 hours (preferably 2 to 3 hours) at 70 to 100 °C (preferably 85 to 95 °C) After treatment, it can be characterized by obtaining by filtration and reduced pressure at 65 ⁇ 75 °C.
  • Desalted lava seawater at 70-100 ° C. (preferably 85-95 ° C.) was added to green tea and treated for 1 to 24 hours (preferably 2 to 3 hours) while maintaining the temperature, followed by filtration and 65 to Obtained green tea extract at 75 ° C. (preferably 68-72 ° C.) under reduced pressure, optionally sterilized using a sterile filter, and dried using methods such as heat evaporation, vacuum evaporation, sun drying or ventilation drying.
  • It can be obtained in the form (for example, green tea extract powder), and the dried green tea extract can be prepared as an aqueous green tea extract by dissolving it in an appropriate amount in an aqueous solution such as distilled water.
  • the green tea extract may be characterized in that it contains a polysaccharide (molecular weight) of 200 ⁇ 300kDa (preferably 240 ⁇ 260kDa).
  • the desalted lava seawater may be prepared by mixing demineralized water obtained by desalting the Jeju lava seawater by reverse osmosis and mineral water obtained by concentrating Jeju lava seawater by electrodialysis.
  • the desalted lava seawater may be prepared by mixing the demineralized water and the mineral water in a volume ratio of 19: 1.
  • the demineralized water is a microfiltration (MF) and / or ultrafiltration (UF) using a micro-filter having a 5 ⁇ m pore size of the collected Jeju lava sea water, any method known in the art, for example, flash evaporation, seawater freezing, reverse osmosis, ion exchange resin, electrodialysis or desalination using a commercially available electrodialysis or demineralization, but is preferably prepared by reverse osmosis , more preferably 1x10 - it is prepared by using 6 ⁇ m reverse osmosis using a membrane filtration (RO) having a standard remove salts dissolved in water lava.
  • RO demineralized water is a microfiltration (MF) and / or ultrafiltration (UF) using a micro-filter having a 5 ⁇ m pore size of the collected Jeju lava sea water, any method known in the art, for example, flash evaporation, seawater freezing, reverse osmosis, ion exchange resin, electro
  • the mineral water is any method known in the art, such as flash evaporation method, seawater freezing method after fine filtration and / or ultrafiltration using a micro-filter having 5 ⁇ m pore size , Reverse osmosis, ion exchange resin, electrodialysis, or by using a commercially available electrodialysis or demineralization, but can be prepared by concentration by electrodialysis is prepared by varying the electrical conductivity value of mineral water It is preferable because the mineral concentration can be adjusted.
  • Prefiltration or “Ultrafiltration” usable in the present invention means that the target solute is fractionated according to the size and structure of the solute, which is a component of the mixed solution, through the pores of the membrane under a certain pressure. It is a process.
  • the solution may be purified by performing a polysulfone (PS) membrane for separation of 0.1 ⁇ m or 750 kDa molecular weight cutoff (MWCO) at 5 to 40 psig and 4 to 60 ° C.
  • PS polysulfone
  • MWCO molecular weight cutoff
  • microfiltration is a process preceding ultrafiltration and is used to separate particles of 0.1 to 10 ⁇ m from solution and to separate polymers having a molecular weight of 1 ⁇ 10 5 g / mol.
  • Microfiltration is also used to remove sediment, protozoa, large bacteria and the like. Microfiltration available in the present invention can be easily used to remove polymers, cell debris.
  • the microfiltration process is carried out using a pressure pump or a vacuum pump at a pressure of 0.1 to 5 m / s, preferably 1 to 3 m / s, and a pressure of 50 to 600 kPa, preferably 100 to 400 kPa.
  • Ultrafiltration is used to separate particles from 0.01 to 0.1 ⁇ m from solution, which generally corresponds to polymers having a molecular weight of 1 ⁇ 10 3 to 1 ⁇ 10 5 Da. Ultrafiltration is used to remove proteins, endotoxins, viruses, and silica.
  • the hardness of the desalted lava sea water may be characterized in that 200 to 300 mg / L.
  • the present invention relates to a pharmaceutical composition (pharmaceutical composition) for improving blood glucose metabolism or improving obesity, which contains the composition for improving blood sugar control as an active ingredient in another aspect.
  • the pharmaceutical composition may further contain pharmaceutical aids such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts for regulating osmotic pressure and / or buffers, and other therapeutically useful substances, and various oral agents in accordance with conventional methods.
  • pharmaceutical aids such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts for regulating osmotic pressure and / or buffers, and other therapeutically useful substances, and various oral agents in accordance with conventional methods.
  • Parenteral dosage forms may be transdermal dosage forms, for example, but not limited to, lotion, ointment, gel, cream, patch or spray formulations.
  • the dosage of the active ingredient is within the level of those skilled in the art, and the daily dosage of the drug depends on various factors such as less progression, onset, age, health condition, complications, etc. of the subject to be administered.
  • the composition may be administered by dividing 1 ⁇ g / kg to 200 mg / kg, preferably 50 ⁇ g / kg to 50 mg / kg, once or three times a day, and the dosage may be determined by any method. Nor does it limit the scope of the invention.
  • compositions containing green tea extracts of the present invention may be used as pharmaceutical preservatives such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for controlling osmotic pressure and other therapeutically useful substances (carriers, excipients, diluents, etc.) It may further contain and can be formulated in various oral or parenteral dosage forms according to conventional methods.
  • preservatives such as preservatives, stabilizers, hydrating or emulsifying accelerators, salts and / or buffers for controlling osmotic pressure and other therapeutically useful substances (carriers, excipients, diluents, etc.) It may further contain and can be formulated in various oral or parenteral dosage forms according to conventional methods.
  • carrier is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the incorporation of many organic compounds into cells or tissues of an organism.
  • excipient is a substance that is added to make it easier to take medicine or to have a certain color and form when the amount of the main medicine is small in the process of preparation of tablets or pills, such as lactose or starch. do.
  • diot is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
  • compositions containing green tea extracts as used herein may be administered to a human patient, as such, or as a pharmaceutical composition in combination with other active ingredients or with a suitable carrier or excipient, such as in combination therapy.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to active ingredients. , Diluents such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine, and glidants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols. .
  • Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
  • Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • the tablets can be prepared by conventional mixing, granulating or coating methods.
  • parenteral administration agent may be, for example, formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, patches, and the like. It is not.
  • compositions according to an embodiment of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
  • Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
  • the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Will be different. Dosage determination based on these factors is within the level of skill in the art.
  • the dosage may preferably be 10 mg / day to 10 g / day, but the dosage does not limit the scope of the invention in any way.
  • the green tea extract of the present invention is a natural substance, it is not toxic at all and can be continuously used in large amounts as a medicine.
  • compositions suitable for use in the present invention include compositions in which the active ingredients comprising green tea extracts are contained in an amount effective to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject to be treated or to prevent, alleviate or alleviate the symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, in particular in terms of the detailed disclosure provided herein.
  • a therapeutically effective amount for the green tea extract used in the methods of the present invention and a composition (compounds) containing it as an active ingredient can be determined initially from cell culture assays. For example, dose can be calculated in an animal model to obtain a range of circulating concentrations that includes an IC 50 (half maximal inhibitory concentration) or EC 50 (half maximal effective concentration) determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficiency of the green tea extracts described herein, or compositions (compounds) containing them as active ingredients are described, for example, LD 50 (fatal to 50% of the population), ED 50 (50% of the population).
  • LD 50 fatal to 50% of the population
  • ED 50 50% of the population
  • IC 50 the dose with therapeutic inhibitory effect for 50% of the population
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 (or IC 50 ).
  • Compounds showing high therapeutic indices are preferred.
  • the data obtained from these cell culture assays can be used to estimate the range of doses used in humans.
  • the dosage or dosage of such compounds is preferably in the range of circulating concentrations including ED 50 (or IC 50 ) in the absence or little toxicity.
  • the present invention relates to a health functional food composition for improving blood sugar metabolism or improving obesity, which contains the composition for improving blood sugar control as an active ingredient in another aspect.
  • the "functional food” or “functional food” means a food that improves the functionality of the general food by adding the green tea extract of the present invention to the general food.
  • Functionality can be roughly divided into physical properties and physiological functions.
  • the extract of the present invention is added to general foods, the physical properties and physiological functions of general foods will be improved, and the present invention provides a food product of such an improved function as a comprehensive 'functional food.
  • Health functional food "or" functional food (health functional food) ".
  • the health functional food containing the green tea extract of the present invention may contain other ingredients and the like which can give a synergistic effect to the main effect within the range of not impairing the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • compositions of the present invention can be used in the form of additives for other foods.
  • the formulation of the dietary supplement containing the green tea extract of the present invention is not particularly limited, but may be formulated into various forms, for example, tablets, granules, drinks, beverages, solutions, emulsions, viscous mixtures, tablets, powders, and the like. Can be.
  • the health functional food administration may be administered by a variety of methods, such as simple drinking, injection, spray or squeeze method.
  • the health functional food of the present invention for example, various foods, candy, chocolate, beverages, gums, tea, vitamin complexes, health supplements and the like, and can be used in the form of powders, granules, tablets, capsules or beverages Can be.
  • the green tea extract of the present invention may be added to food or beverage for the purpose of improving blood sugar metabolism or improving obesity.
  • the amount of the extract in the food or beverage is generally added to the functional food composition of the present invention 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, the health beverage composition is 100 mL It can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g as a reference.
  • the health beverage composition of the present invention has no special limitation except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks.
  • natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose, for example polysaccharides such as maltose and sucrose, and conventional sugars such as dextrin and cyclodextrin. And sugar alcohols such as xylitol, sorbitol, and erythritol.
  • natural flavoring agents such as, tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
  • the proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 mL of the composition of the present invention.
  • the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • the compositions of the present invention may also contain pulp for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
  • the present invention relates to a cosmetic composition for improving blood sugar metabolism or improving obesity, which contains the blood sugar control improving composition as an active ingredient in another aspect.
  • the cosmetic composition is not particularly limited in formulation, and may be appropriately selected as desired.
  • softening cream skin lotion and milk lotion
  • nourishing cream essence
  • nourishing cream massage cream, pack, gel, essence
  • eye cream eye essence
  • cleansing cream cleansing foam
  • cleansing water cleansing water, pack, powder
  • the blood glucose metabolism improvement may be characterized in that the blood glucose drop.
  • Lava sea water defined in the present invention is excavated from 100 to 200m underground, preferably 150m underground in the basement of Handong-ri, Gujwa-eup, Bukjeju-gun, Eastern Jeju, 30-150m underground, preferably 44.35m, 86.35m or 126.35m underground One lava seawater.
  • the desalting process was performed. That is, precision filtration using a water intake by Jeju lava water micro-filter having a 5 ⁇ m pore size (microfiltration, MF) and / or ultra filtration (ultrafiltration, UF) and, 1x10 - station by using a membrane having a 6 ⁇ m standard osmosis filtration (RO) to remove salts dissolved in lava seawater.
  • Jeju lava water micro-filter having a 5 ⁇ m pore size (microfiltration, MF) and / or ultra filtration (ultrafiltration, UF) and, 1x10 - station by using a membrane having a 6 ⁇ m standard osmosis filtration (RO) to remove salts dissolved in lava seawater.
  • Jeju lava seawater taken in order to replenish the demineralized water (demineralized water) with demineralized salt to an appropriate content is mixed with mineral water obtained by electrodialysis (ED) to produce 'demineralized lava seawater', but the volume ratio of demineralized water and mineral water
  • ED electrodialysis
  • the electrodialysis was performed by separating the monovalent cation, the monovalent anion, and the divalent anion by using a membrane to separate the anode.
  • the desalted lava seawater was confirmed to have a specified mineral composition.
  • Table 1 shows the main composition contained in the desalted lava seawater.
  • the demineralized lava seawater had a high Mg content and the water hardness was very high at about 244 mg / L.
  • the hardness of drinking water commercially available in Korea is about 20 to 80 mg / L. 300 mg / L or more).
  • Example 1 Composition Analysis of Green Tea Extract Using Desalted Lava Seawater
  • Table 2 shows the composition (wt%) of the green tea extract prepared using different extracting solvents.
  • the extraction solvent is Jeju freshwater, desalted lava seawater (Production Example 1) or land freshwater.
  • the fat precursor cells were divided into black 96-well plates for fluorescence measurement, and the fat precursor cells were differentiated into adipocytes, and then cultured in a serum-free medium for 16 hours.
  • distilled water (negative control group) or desalted lava seawater, which is an extraction solvent, or green tea extract prepared using the extracting solvent was incubated with a serum-free medium.
  • 100 nM of insulin was treated with the cells to transfer the glucose transporter in the cytoplasm to the cell membrane, followed by further incubation for 30 minutes, and then the medium was removed and washed with warm assay buffer.
  • 2-NBDG fluorescence when the value of 2-NBDG fluorescence is high, it means that the amount of glucose (2-NBDG) that enters adipocytes is large.
  • the adipocytes treated only with distilled water or demineralized lava seawater did not have a statistically significant change in glucose transport ability
  • the green tea extract extracted with demineralized lava seawater was compared with the green tea extract extracted with distilled water.
  • Glucose traffic increased significantly.
  • the green tea extract extracted with distilled water in adipocytes was treated at a high concentration (200 ppm)
  • the glucose transport ability in adipocytes was higher when the green tea extract extracted with demineralized lava seawater was treated at a lower concentration (100 ppm). Therefore, it was confirmed that the use of green tea extract extracted with demineralized lava seawater had a synergistic effect on increasing glucose transport ability of adipocytes.
  • the green tea extract prepared using the desalted lava seawater according to the present invention has a hypoglycemic effect, and thus may be prepared as a medicine, functional food, or cosmetics for improving blood glucose metabolism or improving obesity.
  • Formulation examples 1 to 8 comprising green tea extract prepared using desalted lava seawater desalted from Jeju lava seawater of the present invention as an active ingredient may be commercialized (medicine, food, cosmetics) into various formulations, It can be controlled at an appropriate content ratio, taking into account the functionality, cost and other conditions of the product.
  • the ointment containing the green tea extract manufactured using the desalted lava seawater of this invention was prepared by mixing the components of Table 3 containing an oil phase component and an aqueous phase component.
  • Green tea extract 80 mg, vitamin E 9 mg, vitamin C 9 mg, palm oil 2 mg, vegetable hardened oil 8 mg, lead beetle 4 mg and lecithin 9 mg were prepared using desalted lava seawater, and the soft capsule filling solution was mixed according to a conventional method. . 400 mg per capsule was filled to prepare a soft capsule. In addition, a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
  • Tablets were prepared by tableting the composition 600 mg prepared by mixing 50 mg of green tea extract, 10 mg of vitamin C, 515 mg of crystalline cellulose, 12 mg of carboxymethylcellulose calcium, 8 mg of silicon dioxide, and 5 mg of magnesium stearate, prepared using desalted lava seawater. It was.
  • a massage cream containing a green tea extract prepared by using the desalted lava seawater of the present invention was mixed by mixing the components of Table 5 including an oil phase component and an aqueous phase component.
  • a pack containing the green tea extract prepared by using the desalted lava seawater of the present invention was prepared by mixing the components of Table 6 including an oil phase component and an aqueous phase component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Birds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition pour améliorer la régulation du glucose sanguin, la composition comprenant un extrait de thé vert, laquelle composition est préparée à l'aide d'eau de mer de lave dessalée et, plus spécifiquement, une composition pour améliorer la régulation du glucose sanguin, la composition comprenant, en tant que principe actif, un extrait de thé vert qui est préparé à l'aide d'eau de mer de lave de Jeju dessalée en tant que solvant d'extraction. L'extrait de thé vert préparé à l'aide d'eau de mer de lave dessalée selon la présente invention peut améliorer la concentration en glucose sanguin et peut être utilisé dans la fabrication d'un médicament, d'un aliment fonctionnel et d'un produit cosmétique, ce qui peut réduire le risque d'apparition d'une maladie cardiovasculaire par l'activation de fonctions biologiques.
PCT/KR2017/010124 2016-09-30 2017-09-15 Composition comprenant un extrait de thé vert pour améliorer la régulation du glucose sanguin, préparée à l'aide d'eau de mer de lave dessalée WO2018062733A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0126279 2016-09-30
KR1020160126279A KR102586262B1 (ko) 2016-09-30 2016-09-30 탈염 용암해수를 이용하여 제조한 녹차 추출물을 포함하는 혈당 조절 개선용 조성물

Publications (1)

Publication Number Publication Date
WO2018062733A1 true WO2018062733A1 (fr) 2018-04-05

Family

ID=61762928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010124 WO2018062733A1 (fr) 2016-09-30 2017-09-15 Composition comprenant un extrait de thé vert pour améliorer la régulation du glucose sanguin, préparée à l'aide d'eau de mer de lave dessalée

Country Status (2)

Country Link
KR (1) KR102586262B1 (fr)
WO (1) WO2018062733A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109730952A (zh) * 2019-01-04 2019-05-10 爱思开百朗德生物科技（海门）有限公司 含铁皮石斛的熔岩海水提取工艺

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102556067B1 (ko) * 2020-12-15 2023-07-18 농업회사법인 주식회사 그린로드 부종완화용 애기수박 추출 조성물의 제조방법 및 부종완화용 식품 조성물
KR20230037000A (ko) 2021-09-07 2023-03-15 고려대학교 세종산학협력단 미네랄 및 효소 복합 공정을 이용한 도두꼬투리 추출물의 신규 제조 방법 및 이에 따라 제조된 추출물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040030361A (ko) * 2002-10-01 2004-04-09 그리워 임 반도 심층수 또는 그 농축물을 함유하는 당뇨병의 예방 및치료용 조성물
KR20070089368A (ko) * 2006-02-28 2007-08-31 (주)블루오션월드 식물에 함유된 기능성 물질들의 해양 심층수 용매 추출 방법
KR20090014528A (ko) * 2007-08-06 2009-02-11 주식회사 워터비스 녹차 기능성 성분이 결합된 해양성 천연 유기미네랄 조성물
KR20090126364A (ko) * 2008-06-04 2009-12-09 서희동 해양 심층수로부터 녹차 음료 추출용수를 만드는 방법
KR20100073705A (ko) * 2008-12-23 2010-07-01 제주대학교 산학협력단 항당뇨 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090077572A (ko) * 2008-01-11 2009-07-15 주식회사 바이오랜드 용암해수 탈염 미네랄수를 함유하는 대사증후군 예방 또는치료용 조성물
KR101002589B1 (ko) 2008-04-07 2010-12-21 강원도 고성군 (관리부서 농업기술센터) 해양심층수를 이용한 고기능성 녹차 잎의 생산방법
KR20100124519A (ko) * 2009-05-19 2010-11-29 (주)아모레퍼시픽 녹차 추출물을 함유하는 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040030361A (ko) * 2002-10-01 2004-04-09 그리워 임 반도 심층수 또는 그 농축물을 함유하는 당뇨병의 예방 및치료용 조성물
KR20070089368A (ko) * 2006-02-28 2007-08-31 (주)블루오션월드 식물에 함유된 기능성 물질들의 해양 심층수 용매 추출 방법
KR20090014528A (ko) * 2007-08-06 2009-02-11 주식회사 워터비스 녹차 기능성 성분이 결합된 해양성 천연 유기미네랄 조성물
KR20090126364A (ko) * 2008-06-04 2009-12-09 서희동 해양 심층수로부터 녹차 음료 추출용수를 만드는 방법
KR20100073705A (ko) * 2008-12-23 2010-07-01 제주대학교 산학협력단 항당뇨 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109730952A (zh) * 2019-01-04 2019-05-10 爱思开百朗德生物科技（海门）有限公司 含铁皮石斛的熔岩海水提取工艺
CN109730952B (zh) * 2019-01-04 2021-09-10 现代百朗德生物科技(江苏)有限公司 含铁皮石斛的熔岩海水提取工艺

Also Published As

Publication number Publication date
KR102586262B1 (ko) 2023-10-10
KR20180036111A (ko) 2018-04-09

Similar Documents

Publication Publication Date Title
KR102132655B1 (ko) 구절초 추출물을 포함하는 조성물
KR20140107614A (ko) 메일라드 반응 저해제
KR101782848B1 (ko) 백편두 추출물을 유효성분으로 함유하는 숙취해소 및 알코올성 위장질환의 예방, 개선 또는 치료용 조성물
KR19990014205A (ko) 플라보노이드 및 파피아 가공물을 함유한 조성물
KR101382099B1 (ko) 섬쑥부쟁이 추출물, 이의 분획물, 또는 이로부터 분리된 화합물을 함유하는 항경련용 조성물
WO2018062733A1 (fr) Composition comprenant un extrait de thé vert pour améliorer la régulation du glucose sanguin, préparée à l'aide d'eau de mer de lave dessalée
KR101676751B1 (ko) 감귤류 과피 추출물의 제조방법 및 간 손상 예방, 개선 또는 치료용 조성물
KR102064651B1 (ko) 여주 추출물, 구절초 추출물 및 작약 추출물을 유효 성분으로 포함하는, 당뇨 예방 또는 개선용 조성물
KR101617590B1 (ko) 아로니아, 아사이베리 및 스테비아 추출물을 포함하는 항비만 식품 조성물
KR100829057B1 (ko) 프로폴리스와 한약재를 배합한 혈당저하 식품조성물 및 그제조방법
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
KR20110087420A (ko) 다이어스 캐모마일 추출물을 포함하는 당뇨합병증 치료 또는 예방용 조성물
KR20090077572A (ko) 용암해수 탈염 미네랄수를 함유하는 대사증후군 예방 또는치료용 조성물
CA2493790A1 (fr) Aliment ameliorant la circulation sanguine
KR20200145757A (ko) 아피오스 아메리카나 괴경 추출물의 분획물을 포함하는 알코올성 위염 예방, 개선 또는 치료용 조성물 및 이의 제조방법
KR101083832B1 (ko) 까실쑥부쟁이 추출물을 포함하는 당뇨합병증 치료 또는 예방용 조성물
KR101731152B1 (ko) 다래순 추출물 또는 이의 분획물을 유효성분으로 함유하는 항당뇨 조성물
KR101333982B1 (ko) 섬쑥부쟁이 추출물을 유효성분으로 함유하는 진정 또는 수면유도용 약제학적 조성물
KR102264494B1 (ko) 천연물 복합 소재를 이용한 골관절염의 예방 개선, 또는 치료용 조성물
KR102343245B1 (ko) 감국 지용성 분획 추출물을 유효성분으로 포함하는 아토피의 예방, 개선 또는 치료용 조성물
KR101971986B1 (ko) 참나무겨우살이 추출물을 유효성분으로 포함하는 항암용 조성물
KR101854180B1 (ko) 감귤류 과피 추출물을 포함하는 간 손상 예방 또는 개선용 건강기능식품
KR101910099B1 (ko) 미성숙 감으로부터 가압 열수 방법으로 추출한 추출물 유효성분으로 포함하는 지질대사 개선 또는 항비만용 조성물
KR20080035853A (ko) 미나리 추출물을 유효성분으로 포함하는 숙취해소용조성물 및 이를 이용한 기능성 건강식품
KR101538055B1 (ko) 우르시올이 제거된 옻 추출물의 제조방법 및 상기 방법으로 제조된 옻 추출물의 약침으로서의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17856619

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17856619

Country of ref document: EP

Kind code of ref document: A1